Evidence topic
These reviews start from a claim a reader has already met — on a menu, in an advertisement, in a summary written by someone selling the compound — and test it against what has been published.
The verdict leads. A review that buries its answer under a survey of the literature has failed the reader who arrived with the question.
33 reviews · page 2 of 3
Does elamipretide improve fatigue and exercise capacity?
A 218-person trial in primary mitochondrial myopathy found no improvement in walking distance or fatigue; encouraging Barth syndrome extension results came from a different disease and an uncontrolled phase.
Does kisspeptin-10 treat low testosterone?
Small studies show hormone stimulation in healthy men, but they do not establish symptom improvement or treatment benefit in men with clinical hypogonadism.
Can setmelanotide trial results predict general weight loss?
No. The cited trials enrolled people with specific rare disorders, and their response rates cannot be applied to ordinary obesity or compared directly with unrelated weight-loss trials.
Does BPC-157 work when taken by mouth or as a nasal spray, and how do those forms compare with injection?
That is not known, because no published study has measured how much BPC-157 reaches the bloodstream when it is swallowed or sprayed into the nose, in people or in any animal, and none has compared either route with injection. The claim that it survives stomach acid comes from its originators' own reviews; the one oral trial in people, registered in 2015, has posted no results; and PubMed holds no study of nasal BPC-157 at all. The form does not change its legal position: as of September 2026 no pharmacy may lawfully compound it in any form.
What are the GLOW and KLOW peptide blends, and has either been tested in people?
Neither blend is an approved drug, and no human trial has tested either combination. Injectable GHK-Cu has no lawful compounding route, BPC-157, TB-500 and KPV await FDA action after an advisory vote, and none of the four has a published controlled trial as an injection.
What is the difference between Melanotan I and Melanotan II?
Melanotan I is the research name of afamelanotide, which FDA approved in 2019 as Scenesse, an implant for adults with the rare light-sensitivity disease erythropoietic protoporphyria; Melanotan II is a different, non-selective compound with no approval, whose only tanning-related trial is a three-volunteer pilot from 1996 and whose later human record is mostly case reports of harm. No approved product is indicated for tanning, and material sold under either name is not Scenesse.
Which peptides sold for weight loss are actually FDA-approved for it?
Four, each for a specific label: semaglutide (Wegovy), tirzepatide (Zepbound) and liraglutide (Saxenda) for chronic weight management, and setmelanotide (Imcivree) only for rare genetic and hypothalamic obesity; tesamorelin is approved for a narrower use, AOD-9604 failed its human weight trial, and MOTS-c and retatrutide have no approved use at all.
What is the Wolverine stack, and has BPC-157 with TB-500 been tested in people?
No trial has tested the pair. The Wolverine stack is a marketplace name for BPC-157 used together with TB-500; the only human data on the combination are four patients in one uncontrolled chart review, a rat study found no added benefit from combining them, neither peptide may be lawfully compounded while FDA acts on a July 2026 advisory vote, and both are prohibited in sport.
Did the randomized trials of secretin for autism support the treatment?
No. A scoped census returns 19 randomized-type records; all 19 were opened, 16 are randomized trials of secretin in autism, and every one of the 16 reports no benefit on its primary measures.
Do thymulin's eight trial-type records show that the peptide has been tested in people?
No. All eight were opened: seven measure the body's own thymulin as a marker of zinc status inside zinc-supplementation trials, and the eighth administers a different molecule, a synthetic analogue, in a 1989 pilot.
Do the trial records for GHRP-2 and GHRP-6 support the uses the compounds are sold for?
No. All 115 titles were read: they are overwhelmingly pituitary provocation and diagnostic studies, giving the peptide to measure hormone release rather than to treat anything, and the GHRP-6 count also draws in neighboring compounds and animal work.
Does the evidence support the lifespan and telomerase claims made for Epitalon?
No. The telomerase finding is a 2003 cell-culture report; the nine trial-type human records belong almost entirely to epithalamin, a glandular extract, appear in Russian journals or their translated editions, and the most recent was published in 2011.
A review argues from the ledger; the ledger itself is published as reference tables, and every molecule’s dated posture is in the molecule index. Terms of art are defined in the glossary.